Skip to main content
OpenTrials
Completed

NCT Number: NCT04487171

Screening for Postpartum Depression and Associated Risk Factors Among Women Who Deliver in Four Hospital in France During the COVID-19 Epidemic

Postpartum depression (PPD) represent around 15% of birth in developed countries. The context of the COVID-19 epidemy represents a possible source of additional emotional distress. The objective of this study is to determine the screening prevalence and risk factors of postpartum depression, among women who deliver in fourth hospital in the North of France in the context of the COVID epidemy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Postpartum Depression COVID-19 Coronaviridae Infections Coronavirus Infections Covid19 Depression, Postpartum Depressive Disorder Female Urogenital Diseases and Pregnancy Complications Infections Lung Diseases Mental Disorders Mood Disorders Nidovirales Infections Pneumonia Pneumonia, Viral Pregnancy Complications Prevalence Puerperal Disorders RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Social Distance Urogenital Diseases Virus Diseases

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

CHU Amiens

Amiens, 80480, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Single baby delivery
  • alive new born child without admission in neonatal intensive care unit
  • French-speaking mother
  • mother older than 18 years old

Exclusion criteria

  • Patients who refuses the inclusion

Treatment and study plan

Questionnaire

Other

The mothers were administrated three questionnaires, (i) the Edinburgh Postnatal Depression Scale (EPDS), (ii) the State-Trait Anxiety Inventory (STAI-YA), and (iii) the Mother-to-Infant Bonding Scale (MIBS) in two stages, on days 2-3 after delivery and during a phone call between days 25-35.

Primary outcomes

  1. Variation of prevalence of clinically-significant post-partum depressive symptoms

    Time frame: up to 35 days after delivery

    Variation of prevalence of clinically-significant post-partum depressive symptoms

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire, Amiens

Other

Collaborators

  • Central Hospital Saint Quentin
  • Centre Hospitalier Intercommunal de Compiègne-Noyon
  • Centre Hospitalier de Beauvais

Registry information

Acronym: COVIE-19/20

Important dates

Study start
2020
Primary completion
2024
Study completion
2024
First posted
Jul 27, 2020
Registry last updated
Jun 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.